Health-related quality of life and use of medication with anticholinergic activity in patients with multiple myeloma

[1]  M. Veríssimo,et al.  A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity , 2023, Pharmaceutics.

[2]  Eliz Cassieli Pereira Pinto,et al.  [The use of anticholinergic drugs and associated factors in middle-aged adults and the elderly]. , 2022, Ciencia & saude coletiva.

[3]  C. Cháfer-Pericás,et al.  CRIDECO Anticholinergic Load Scale: An Updated Anticholinergic Burden Scale. Comparison with the ACB Scale in Spanish Individuals with Subjective Memory Complaints , 2022, Journal of personalized medicine.

[4]  S. Bhatia,et al.  The association of polypharmacy with functional status impairments, frailty, and health-related quality of life in older adults with gastrointestinal malignancy - Results from the Cancer and Aging Resilience Evaluation (CARE) registry , 2022, Journal of Geriatric Oncology.

[5]  I. Benseñor,et al.  Anticholinergic burden and cognitive performance: cross-sectional results from the ELSA-Brasil study , 2021, European Journal of Clinical Pharmacology.

[6]  U. Haug,et al.  Anticholinergic burden: First comprehensive analysis using claims data shows large variation by age and sex , 2021, PloS one.

[7]  C. M. Pádua,et al.  Validity and reliability of the QLQ-MY20 module for assessing the health-related quality of life in Brazilians with multiple myeloma , 2021, Current medical research and opinion.

[8]  L. Peng,et al.  Quality of Life among Community-Dwelling Middle-Aged and Older Adults: Function Matters More than Multimorbidity. , 2021, Archives of gerontology and geriatrics.

[9]  A. Artz,et al.  Characterize, Optimize, and Harmonize: Caring for Older Adults With Hematologic Malignancies. , 2021, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[10]  F. Zhou,et al.  Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects , 2021, Frontiers in Medicine.

[11]  M. Zins,et al.  Anticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES Study , 2021, Drug Safety.

[12]  G. Abel,et al.  Defining multimorbidity and its impact in older united states veterans newly treated for multiple myeloma. , 2021, Journal of the National Cancer Institute.

[13]  Hee-Won Jung,et al.  Clinical outcomes associated with anticholinergic burden in older hospitalized patients with advanced cancer: a single-center database study , 2021, Supportive Care in Cancer.

[14]  R. Luben,et al.  Baseline anticholinergic burden from medications predicts poorer baseline and long‐term health‐related quality of life in 16 675 men and women of EPIC‐Norfolk prospective population‐based cohort study , 2020, Pharmacoepidemiology and drug safety.

[15]  R. Luben,et al.  Anticholinergic medication exposure predicts poor physical capability: Findings from a large prospective cohort study in England , 2020, Maturitas.

[16]  Y. Loke,et al.  Anticholinergic Burden Measures Predict Older People's Physical Function and Quality of Life: A Systematic Review. , 2020, Journal of the American Medical Directors Association.

[17]  D. Rondelli,et al.  Polypharmacy and potentially inappropriate medication use is highly prevalent in multiple myeloma patients and is improved by a collaborative physician–pharmacist clinic , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[18]  Limei Xu,et al.  Education level as a predictor of survival in patients with multiple myeloma , 2020, BMC Cancer.

[19]  S. Rajkumar,et al.  Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management , 2020, American journal of hematology.

[20]  E. Skovlund,et al.  Effect of Clinical Geriatric Assessments and Collaborative Medication Reviews by Geriatrician and Family Physician for Improving Health-Related Quality of Life in Home-Dwelling Older Patients Receiving Polypharmacy: A Cluster Randomized Clinical Trial. , 2020, JAMA internal medicine.

[21]  N. Aaronson,et al.  Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. , 2020, Journal of clinical epidemiology.

[22]  E. Umit,et al.  Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[23]  A. Kullaa,et al.  Anticholinergic Burden and Dry Mouth in Middle-Aged People , 2019, JDR clinical and translational research.

[24]  A. Vyas,et al.  Association between polypharmacy and health-related quality of life among cancer survivors in the United States , 2019, Journal of Cancer Survivorship.

[25]  R. Warsame,et al.  Patient Reported Outcomes Have Arrived: A Practical Overview for Clinicians in Using Patient Reported Outcomes in Oncology. , 2019, Mayo Clinic proceedings.

[26]  A. Dispenzieri,et al.  Characteristics of long‐term survivors with multiple myeloma: A National Cancer Data Base analysis , 2019, Cancer.

[27]  C. Simonelli,et al.  Quality of life in multiple myeloma: considerations and recommendations , 2019, Expert review of hematology.

[28]  P. Kapoor,et al.  Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population , 2019, Current Hematologic Malignancy Reports.

[29]  A. M. Reis,et al.  Development of a Brazilian anticholinergic activity drug scale , 2019, Einstein.

[30]  J. Hanlon,et al.  American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults , 2019, Journal of the American Geriatrics Society.

[31]  M. Zins,et al.  Anticholinergic drug use and cognitive performances in middle age: findings from the CONSTANCES cohort , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[32]  D. Reid,et al.  A high anticholinergic burden is associated with a history of falls in the previous year in middle-aged women: findings from the Aberdeen Prospective Osteoporosis Screening Study. , 2018, Annals of epidemiology.

[33]  G. Abel,et al.  Frailty and the management of hematologic malignancies. , 2018, Blood.

[34]  H. Payette,et al.  Association Between Anticholinergic Drug Use and Health-Related Quality of Life in Community-Dwelling Older Adults , 2017, Drugs & Aging.

[35]  G. Colditz,et al.  Geriatric Assessment in Older Adults with Multiple Myeloma , 2016, Journal of the American Geriatrics Society.

[36]  A. Abernethy,et al.  Anticholinergic Drug Burden in Noncancer Versus Cancer Patients Near the End of Life. , 2016, Journal of pain and symptom management.

[37]  T. R. Osborne,et al.  The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study , 2016, BMC Cancer.

[38]  D. Esseltine,et al.  The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials , 2016, British journal of haematology.

[39]  A. Hui,et al.  Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life , 2015, Supportive Care in Cancer.

[40]  Paul Gallagher,et al.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 , 2014, Age and ageing.

[41]  C. Paiva,et al.  Further evaluation of the EORTC QLQ-C30 psychometric properties in a large Brazilian cancer patient cohort as a function of their educational status , 2014, Supportive Care in Cancer.

[42]  R. Ciconelli,et al.  Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients , 2011, Clinics.

[43]  A. Abernethy,et al.  Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches , 2009, Palliative medicine.

[44]  R. Hájek,et al.  An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. , 2007, European journal of cancer.

[45]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[46]  H. Adami,et al.  Multiple myeloma: A review of the epidemiologic literature , 2007, International journal of cancer.

[47]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.